Gilead’s research and development chief is stepping down after nearly three decades at the company, concluding a run in which he steered the development of pioneering blockbuster therapies for HIV and hepatitis C but more recently became the target of Wall Street ire amid Gilead’s struggles to find a third act.

Norbert Bischofberger will leave his post at the end of April but will stay with the company through July, Gilead (GILD) announced on Monday. The company did not give a reason for his departure, but the move offers Gilead a chance to freshen its uppermost ranks without shaking up its strategy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy